Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

TECARTUS™ Discovered for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Kite discovered Tecartus™ (brexucabtageneautoleucel, formerly KTE-X19), a novel Chimeric Antigen Receptor (CAR) T for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL).

Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy suitable for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Hence, the newly approved CAR T cell therapy for mantle cell lymphoma patients indicates a new frontier in the treatment of this disease.

MCL is a rare type of cancerous B-cell non-Hodgkin lymphoma that typically grows from cells that reside in the lymph nodes mantle region and mainly affecting middle-aged or older adults.Most of the patients experience frequent relapse after initial treatment and moreover the cause of MCL is unknownand at the same time it is incurable.

Some of the adverse symptomsof patients with MCL include painless swelling in the armpit, neck or groin region, unexplained weight loss, night sweats, fever with no obvious cause, anaemia, diarrhoea, loss of appetite, sickness (nausea) and easy bruising or bleeding.

U.S.Food and Drug Administration (FDA) grants Tecartus™ (brexucabtageneautoleucel, formerly KTE-X19) the first and only approved CAR T cell therapy for treating relapsed or refractory mantle cell lymphoma (r / r MCL).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024